BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Uterine cancer AND FGFR2, BFR-1, 2263, ENSG00000066468, TK14, BEK, CD332, JWS, TK25, ECT1, CEK3, K-SAM, CFD1, KGFR
98 results:

  • 1. Association of tet methylcytosine dioxygenase 2 and 5-hydroxymethylcytosine in endometrioid adenocarcinoma and its clinical significance.
    Kuang L; Zhang J; Li Y; Wang Q; Liu J; Zhang B
    BMC Womens Health; 2024 Mar; 24(1):188. PubMed ID: 38515066
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. A rare case of extrarenal Wilms tumor of the uterine corpus: comprehensive genomic profile and review of the literature.
    Alessandrini L; Guerriero A; Munari G; Del Forno B; Santoro L; Marchetti M; Nardin M; Tozzi R; Fassan M; Dei Tos AP
    Pathologica; 2023 Dec; 115(6):333-340. PubMed ID: 38180141
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Identification of a prognostic model based on immune and hypoxia-related gene expressions in cervical cancer.
    Wang L; Wang C; He Y; Jin M; Lin L; Jiao X; Hu X; Wang Y
    J Obstet Gynaecol; 2023 Dec; 43(2):2277242. PubMed ID: 37938121
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Functional Distinctions of Endometrial cancer-Associated Mutations in the Fibroblast Growth Factor Receptor 2 Gene.
    Dixit G; Pappas BA; Bhardwaj G; Schanz W; Maretzky T
    Cells; 2023 Sep; 12(18):. PubMed ID: 37759450
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Integrative multi-omic cancer profiling reveals DNA methylation patterns associated with therapeutic vulnerability and cell-of-origin.
    Liang WW; Lu RJ; Jayasinghe RG; Foltz SM; Porta-Pardo E; Geffen Y; Wendl MC; Lazcano R; Kolodziejczak I; Song Y; Govindan A; Demicco EG; Li X; Li Y; Sethuraman S; Payne SH; Fenyö D; Rodriguez H; Wiznerowicz M; Shen H; Mani DR; Rodland KD; Lazar AJ; Robles AI; Ding L;
    Cancer Cell; 2023 Sep; 41(9):1567-1585.e7. PubMed ID: 37582362
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. A novel DNA damage repair-related gene signature predicting survival, immune infiltration and drug sensitivity in cervical cancer based on single cell sequencing.
    Xiang X; Kang J; Jiang J; Zhang Y; Zhang Y; Li L; Peng X
    Front Immunol; 2023; 14():1198391. PubMed ID: 37449209
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. The Significance of Human Papillomavirus Receptors Related Genetic Variants in Cervical cancer Screening.
    Xie H; Wei M; Yao L; Liu Y; Xie X; Li X
    Microbiol Spectr; 2023 Aug; 11(4):e0511722. PubMed ID: 37358427
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. WIF1 was downregulated in cervical cancer due to promoter methylation.
    Wang Y; Yuan S; Ma J; Liu H; Huang L; Zhang F; Wang X
    Acta Biochim Pol; 2023 Jun; 70(2):419-423. PubMed ID: 37306343
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. fgfr2 mutations promote endometrial cancer progression through dual engagement of EGFR and Notch signalling pathways.
    Dixit G; Gonzalez-Bosquet J; Skurski J; Devor EJ; Dickerson EB; Nothnick WB; Issuree PD; Leslie KK; Maretzky T
    Clin Transl Med; 2023 May; 13(5):e1223. PubMed ID: 37165578
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Paiteling induces apoptosis of cervical cancer cells by down-regulation of the E6/E7-Pi3k/Akt pathway: A network pharmacology.
    Liu Y; Zheng P; Jiao T; Zhang M; Wu Y; Zhang X; Wang S; Zhao Z
    J Ethnopharmacol; 2023 Apr; 305():116062. PubMed ID: 36535331
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Histopathological and molecular findings in 98 cases of endometrial carcinoma: MMR, p53 and next generation sequencing.
    Karabağ S; Şentürk M; Söğüt FC; Ergül ÖS; Ersoy T
    Pathol Res Pract; 2023 Jan; 241():154275. PubMed ID: 36528987
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Spatial expression of the fgfr2b splice isoform and its prognostic significance in endometrioid endometrial carcinoma.
    Sengal AT; Smith D; Snell CE; Leung S; Talhouk A; Williams ED; McAlpine JN; Pollock PM
    J Pathol Clin Res; 2022 Nov; 8(6):521-537. PubMed ID: 35866380
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Endometrial, Ovarian, and Peritoneal Involvement by Endometrioid Carcinoma, Yolk Sac Tumor, and Endometriosis: Molecular Evidence for a Shared Precursor.
    Halling GC; Udager AM; Skala SL
    Int J Gynecol Pathol; 2023 May; 42(3):247-253. PubMed ID: 35639393
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Histopathologic and Molecular Characterization of uterine Leiomyoma-like Inflammatory Myofibroblastic Tumor: Comparison to Molecular Subtypes of uterine Leiomyoma.
    Kuisma H; Jokinen V; Pasanen A; Heikinheimo O; Karhu A; Välimäki N; Aaltonen L; Bützow R
    Am J Surg Pathol; 2022 Aug; 46(8):1126-1136. PubMed ID: 35426837
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Biomolecular and Genetic Prognostic Factors That Can Facilitate Fertility-Sparing Treatment (FST) Decision Making in Early Stage Endometrial cancer (ES-EC): A Systematic Review.
    Tanos P; Dimitriou S; Gullo G; Tanos V
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269800
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Distinct Genomic Landscapes in Early-Onset and Late-Onset Endometrial cancer.
    Choi J; Holowatyj AN; Du M; Chen Z; Wen W; Schultz N; Lipworth L; Guo X
    JCO Precis Oncol; 2022 Feb; 6():e2100401. PubMed ID: 35108035
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Comprehensive immunomolecular profiling of endometrial carcinoma: A tertiary retrospective study.
    Victoor J; Borght SV; Spans L; Lehnert S; Brems H; Laenen A; Vergote I; Van Gorp T; Van Nieuwenhuysen E; Han S; Timmerman S; Van Rompuy AS; Vanden Bempt I
    Gynecol Oncol; 2021 Sep; 162(3):694-701. PubMed ID: 34253388
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Expression of the E5 Oncoprotein of HPV16 Impacts on the Molecular Profiles of EMT-Related and Differentiation Genes in Ectocervical Low-Grade Lesions.
    Ranieri D; French D; Raffa S; Guttieri L; Torrisi MR; Belleudi F
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207106
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Recurrent urothelial carcinoma-like FGFR3 genomic alterations in malignant Brenner tumors of the ovary.
    Lin DI; Killian JK; Venstrom JM; Ramkissoon SH; Ross JS; Elvin JA
    Mod Pathol; 2021 May; 34(5):983-993. PubMed ID: 33077920
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
    Sootome H; Fujita H; Ito K; Ochiiwa H; Fujioka Y; Ito K; Miura A; Sagara T; Ito S; Ohsawa H; Otsuki S; Funabashi K; Yashiro M; Matsuo K; Yonekura K; Hirai H
    Cancer Res; 2020 Nov; 80(22):4986-4997. PubMed ID: 32973082
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 5.